Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers
OUTLINE: This is an observational study.
Patients undergo tissue sample collection obtained from standard of care surgical resection or biopsy for SmartMatch laboratory analysis and have their medical records reviewed on study.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Histologically confirmed rare gynecologic malignancy, including but not limited to those listed
Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated
Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate organ function to receive systemic therapy as determined by the treating oncologist (protocol does not specify thresholds because therapy is not mandated)
Ability to understand and willingness to sign informed consent
Willingness to allow data abstraction from the electronic health record for study endpoints
You may not be if
Lack of tumor tissue suitable for SmartMatch analysis
Purely borderline tumors or benign ovarian/uterine neoplasms
Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy
Inability to provide informed consent or comply with study procedures
